Zobrazeno 1 - 10
of 201
pro vyhledávání: '"Ronald M, Ferguson"'
Autor:
Amer Rajab M.D., Ph.D., Jill Buss, Elizabeth Diakoff, Gregg A. Hadley, Kwame Osei, Ronald M. Ferguson
Publikováno v:
Cell Transplantation, Vol 17 (2008)
To date, the portal vein has been the primary site for clinical islet transplantation. Despite success, potential complications such as portal vein thrombosis still exist. The kidney subcapsule has been used successfully in rodent models of islet tra
Externí odkaz:
https://doaj.org/article/8460803dd17c40adbc50140a1c47a721
Autor:
E. Steve Woodle, Arthur J. Matas, Minnie M. Sarwal, D. K. Granger, Dixon B. Kaufman, John S. Gill, Ronald M. Ferguson
Publikováno v:
Clinical Transplantation. 25:457-467
Steroids are associated with a myriad of post-transplant side effects. Therefore, as new immunosuppressive drugs have been developed, attempts have been made to minimize steroid exposure. Sirolimus (SRL) has been demonstrated to have efficacy in earl
Autor:
Gregg A. Hadley, Ronald P. Pelletier, Patrick W. Adams, Ronald M. Ferguson, Mitchell L. Henry, Zhangsheng Yu
Publikováno v:
Ibnosina Journal of Medicine and Biomedical Sciences. :7-15
Background: Chronic renal allograft loss is considered as immunologically mediated when donor-specific alloantibodies are detected. However, remotely detected alloantibodies with lack of detection more proximate to graft loss occurrence may obscure t
Autor:
Ronald P. Pelletier, Todd E. Pesavento, Tibor Nadasdy, Amy Lehman, Ronald M. Ferguson, Anjali A. Satoskar, Daniel D. Sedmak, Gyongyi Nadasdy, Mitchell L. Henry
Publikováno v:
Clinical Transplantation. 22:61-67
Background: In the early post-transplant period, renal allograft rejection with diffuse peritubular capillary (PTC) C4d deposition predicts poor graft survival. In the late post-transplant setting, that is, one or more yr after transplantation, the i
Autor:
Malika Cremer, Alan G. Jardine, Ralph Preiss, Rowan G. Walker, Federico Juarez, Marek Ostrowski, Josep M. Grinyó, Federico Oppenheimer, Shamkant Mulgaonkar, Armando Torres, Ronald M. Ferguson, Marian Klinger
Publikováno v:
Transplantation. 83:645-648
The novel immunomodulator FTY720 has been associated with a mild reduction in heart rate (HR) in clinical trials. A total of 421 patients (FTY720, n=94; mycophenolate mofetil [MMF], n=327) underwent 2-day electrocardiogram and 24-h Holter monitoring.
Autor:
Mitchell L. Henry, Amer Rajab, Gyongyi Nadasdy, Ronald P. Pelletier, Anjali A. Satoskar, Ronald M. Ferguson, Arun Kumar Tewari, Jeffrey Cotrill, Tibor Nadasdy
Publikováno v:
Transplantation. 82:645-650
Background Since using an immunosuppression regimen that includes rapamycin, we have occasionally encountered renal transplant patients who develop unexpected severe acute renal dysfunction. Biopsies obtained in these recipients demonstrate acute tub
Autor:
Shamkant Mulgaonkar, Federico Oppenheimer, A. Knoflach, Ronald M. Ferguson, Rowan G. Walker, U. Kunzendorf, H. Tedesco, Graeme R. Russ, Y. Patel
Publikováno v:
American Journal of Transplantation. 6:1848-1857
FTY720 is a novel immunomodulator being investigated for rejection prophylaxis in renal transplantation when combined with full-dose cyclosporine (CsA; FDC). This 1-year phase II study compared FTY720 plus FDC (Neoral) with FTY720 plus reduced-dose C
Publikováno v:
Clinical Transplantation. 20:10-18
Our transplant centre began a prospective, randomized trial of steroid withdrawal in low risk renal transplant recipients on triple immunosuppression consisting of mycophenolate mofetil (MMF), microemulsion cyclosporine (CSA), and prednisone. One hun
Autor:
Ronald P. Pelletier, Ronald M. Ferguson, Cherri Bott, Gyongyi Nadasdy, Tibor Nadasdy, Daniel J. Cowden
Publikováno v:
Human Pathology. 36:1178-1185
Detection of peritubular capillary (PTC) C4d deposition in tissue sections of renal allograft biopsies became an important aid in the diagnosis of antibody-mediated rejection. Pathologists in many major transplant centers now routinely stain renal al
Publikováno v:
Clinical Transplantation. 19:779-784
Mycophenolate mofetil (MMF), a mycophenolic acid prodrug, is a highly effective adjunct immunosuppressive agent in transplant therapy. Although MMF is generally well tolerated, optimal therapy may be limited by adverse effects, in particular gastroin